ライフサイエンスコーパス: excluded patients

1 Excluded patients included those who had not been residents i

2 t ventricular systolic function and low symptom burden, and excluded patients with left main disease.

3 diagnosed less than 1 year before the date of enrolment and excluded patients with any other malignancies.

4 e included patients who received mechanical ventilation and excluded patients who received a tracheostomy, had a do-not-r

5 trials that led to US Food and Drug Administration approval excluded patients with central nervous system (CNS) involveme

6 ulation that analysed patients by randomised allocation but excluded patients found ineligible after randomisation.

7 The 2 clinical trials that assessed this device excluded patients thought not to be candidates for OAC.

8 a; however, studies using the WatchPAT device have thus far excluded patients with arrhythmias due to the potential effec

9 ver, studies of novel cancer therapeutics have historically excluded patients with HIV.

10 However, these trials largely excluded patients aged 70 years and over or with higher level

11 -treat basis, with an additional per-protocol analysis that excluded patients randomly assigned to the intervention group

12 f these products were approved on the basis of designs that excluded patients who could not tolerate the drugs, had early

13 indings remained stable in sensitivity analysis models that excluded patients with diabetes mellitus.

14 s, overall survival (OS), and time-to-next-treatment (TNT) (excluded patients who died without starting second-line treat

15 amin K antagonist oral anticoagulants (NOACs) with warfarin excluded patients with moderate/severe mitral stenosis or mec

16 We excluded patients detained under sections of the Mental Healt

17 We excluded patients if they were hepatitis B-co-infected or hep

18 We excluded patients previously treated with an agent targeting

19 We excluded patients receiving end-of-life care.

20 We excluded patients transferred from another hospital and those

21 We excluded patients who did not have a radiographic tumour asse

22 We excluded patients who died during initial hospitalization or

23 We excluded patients who had acute or recent gastrointestinal bl

24 We excluded patients who had dysglycemia at baseline and those w

25 We excluded patients who had end-stage kidney disease or AKI at

26 We excluded patients who had previously been enrolled in the stu

27 We excluded patients who had previously received any haemorrhoid

28 We excluded patients who had received antiviral treatment in the

29 We excluded patients who needed emergency medical treatment or i

30 We excluded patients who underwent surgical adrenalectomy, had a

31 We excluded patients who were already taking a beta-blocker or w

32 We excluded patients whose diagnosis had changed during follow-u

33 We excluded patients with a non-ICU policy or with no curative t

34 We excluded patients with a radiological or clinical diagnosis o

35 We excluded patients with a severe illness that might lead to th

36 We excluded patients with contraindications to both deceased don

37 We excluded patients with cutaneous or non-severe systemic masto

38 We excluded patients with left main or ostial right coronary art

39 We excluded patients with less than 3 years' follow-up, prevalen

40 We excluded patients with metastasis, node-positive disease, or

41 We excluded patients with pre-existing risk factors for iron def

42 We excluded patients with previous cancer and followed up the re

43 We excluded patients with prior implantable cardioverter-defibri

44 We excluded patients younger than 18 years and those with advanc

45 We excluded patients younger than 18 years, those with trauma or

46 For acute kidney injury analysis, we excluded patients achieving acute kidney injury criteria in t

47 To minimize confounding by poor and declining health, we excluded patients who experienced progression or died within

48 Patients with melanoma, thyroid, or colorectal cancer were excluded; patients with non-small-cell lung cancer were later

49 Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline

50 imary and secondary analyses in the per-protocol set, which excluded patients with non-completion of the primary endpoint